NAD+ precursors

Oral compounds such as nicotinamide riboside and NMN that raise blood NAD+ levels reliably, with human functional outcomes that remain small and inconsistent.

What NAD+ is

NAD+ is a coenzyme required for hundreds of reactions, including the ones that convert food into usable energy. It is also consumed as a substrate by enzymes involved in DNA repair and by the sirtuin family, which is why it became a longevity target.

Tissue NAD+ declines with age in animal models and in some human tissues. That observation is the foundation of the entire category.

What the human trials show

Oral nicotinamide riboside raises blood NAD+ measurably and is well tolerated in trials up to about 12 weeks. NMN has done the same in several smaller studies. That part is not in doubt.

What remains unsettled is whether the increase produces a functional benefit in healthy adults. Individual trials have reported reduced blood pressure in a subgroup with elevated readings, and improved muscle insulin sensitivity in prediabetic postmenopausal women, but the effects are modest, the studies are small, and results do not consistently replicate.

Oral compared with injection

Injected NAD+ bypasses digestion, which is the usual argument for it. Whether it enters cells more effectively is a separate question, since NAD+ is generally broken down to precursors before cellular uptake, and there are no randomized comparisons of injected NAD+ against an oral precursor for any functional outcome.

Baseline offers NAD+ as a program add-on, and the reason we describe it as supportive rather than proven is that the trial base does not yet earn a stronger word.

Baseline offers NAD+ as an add-on to a program. Speak with a Baseline consultant first, and an independent licensed provider decides whether it fits.

References

  1. Martens CR, et al. Chronic nicotinamide riboside supplementation is well-tolerated and elevates NAD+ in healthy middle-aged and older adults. Nat Commun. 2018.
  2. Yoshino M, et al. Nicotinamide mononucleotide increases muscle insulin sensitivity in prediabetic women. Science. 2021.
  3. Rajman L, Chwalek K, Sinclair DA. Therapeutic potential of NAD-boosting molecules: the in vivo evidence. Cell Metab. 2018.